Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis drugs.

Get a deeper insight into the potential performance of Biogen (BIIB) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for so...

In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.

Biogen Inc. NASDAQ: BIIB has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology comp...

Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing,...

BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.

Sales of an Alzheimer's disease treatment were better than expected, but that and a quarterly beat wasn't enough to offset below-consensus EPS outlook.

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.  Th...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.

Biogen Inc. BIIB will release its fourth-quarter financial results, before the opening bell, on Wednesday, Feb. 12, 2025.

Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quart...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment w...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said.

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option LEQEMBI is the only FDA-approved an...